Companies › Merus
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MCLA-129 bispecific IgG1 antibody targeting EGFR and c-MET receptor tyrosine kinases | EGFR, MET | Phase 1 | Non-Small Cell Lung Cancer Metastatic | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04868877 | MCLA-129 | Phase 1 | Non-Small Cell Lung Cancer Metastatic | Oncology | Oct 2026 |
AstraZeneca Shanghai Henlius Biotech Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Betta Pharmaceuticals Allist Pharmaceuticals Dizal Pharmaceuticals Pierre Fabre Medicament Jiangsu Hansoh Pharmaceutical
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.